Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 124,414 · Balance 89,062 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 89,062 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.64 · Expires 2028-07-31 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-23 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2022 Filed May 24, 2022 23:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 1,081 | $8.93 | $9,653.33 |
DisclosureSEC source: 0001415889-22-005627 · form4-05242022_040525.xml · nonDerivative · entry 2 Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,990 F2 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 5/17/21. Read SEC document |
| May 20, 2022 Filed May 24, 2022 23:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,200 | $8.74 | $19,228.00 |
DisclosureSEC source: 0001415889-22-005627 · form4-05242022_040525.xml · nonDerivative · entry 1 Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,071 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,356 | $10.16 | $23,946.62 |
DisclosureSEC source: 0001415889-22-002174 · form4-03022022_040301.xml · nonDerivative · entry 1 Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,271 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 5/17/21. F2 · price: This transaction was executed in multiple trades at prices from $10.02 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 23:22 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 11,824 | $9.61 | $113,628.64 |
DisclosureSEC source: 0001415889-22-001695 · form4-02232022_030255.xml · nonDerivative · entry 1 Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,627 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 00:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011076 · edgar.xml · nonDerivative · entry 1 Farnum Rhonda · CIK 0001898490 · SVP, Comm & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,451 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.